Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Diabetes mellitus type 2 is a long-term metabolic disorder that is primarily characterized by
insulin resistance, relative insulin deficiency and hyperglycemia. Our hypotheses is that
liver would be the primary organ responsible for the metabolic disorder because of some
unknown defects, where sugar would not be efficiently converted to glycogen and fat, leading
to hyperglycemia. The constant hyperglycemia would keep pressure on beta-cells in the
pancreas to eventually exhaust their ability to produce and secret sufficient amount of
insulin, exacerbating the disease. The Immunotherapy would enhance the liver functions and
correct the abnormal sugar metabolism. In addition, the ex vivo activated cells produce and
secret growth factors which would help endothelial cells of blood vessels to reproduce and
grow, resulting in reduced arteriosclerosis.
Phase:
Phase 1
Details
Lead Sponsor:
B & Y Technologies
Collaborators:
Guangzhou No.12 People's Hospital The 12th People's Hospital of Shenzhen City